2022

A clinical trial with IDIBELL participation confirms the benefits of a new drug in heart failure

Dapagliflozin significantly reduces the risk of cardiovascular death and hospitalizations for heart failure (HF).

A clinical trial with IDIBELL participation confirms the benefits of a new drug in heart failure Read More »

Early physical therapy in patients with severe COVID-19 can reduce hospitalization days

A retrospective study by IDIBELL and the Bellvitge University Hospital shows that starting physical rehabilitation of patients admitted to the UCRI with severe COVID-19 before seven days reduces hospitalization time.

Early physical therapy in patients with severe COVID-19 can reduce hospitalization days Read More »

An incidental finding in prostate biopsies allows the diagnosis of a previously unsuspected systemic disease

The research, led by researchers from IDIBELL and the Bellvitge University Hospital (HUB), has established that when amyloidosis is detected in the prostate, it is almost always the TTR-type systemic variant of the disease associated with aging.

An incidental finding in prostate biopsies allows the diagnosis of a previously unsuspected systemic disease Read More »

Tobacco control in the 21st century: A global and local perspective

Among recent achievements, first of all, the entry into force of the WHO Framework Convention on Tobacco Control in 2005 stands out, which has surely been the most important milestone, not only for tobacco control, but as a paradigm of public health on a global scale.

Tobacco control in the 21st century: A global and local perspective Read More »

Five IDIBELL researchers star in the Women of Science section of the television program Aula L’H

The Aula L’H program on L’Hospitalet digital television, specialized in education, together with the Institut Bellvitge and IDIBELL, have carried out, throughout the 2021-22 academic year, a complete edition of the Women of Science section, entirely dedicated to disseminating the research work, the research career and the personality of five IDIBELL scientists.

Five IDIBELL researchers star in the Women of Science section of the television program Aula L’H Read More »

Validated a tool that assesses the risk of sudden death due to a heart disease

Twenty-nine reference centers from the United States, Canada, the Netherlands, Italy, France, and Spain, including IDIBELL, have participated in an international multicenter study that validated a model for predicting the risk of ventricular arrhythmias and sudden death in arrhythmogenic cardiomyopathy of the right ventricle (ARVC).

Validated a tool that assesses the risk of sudden death due to a heart disease Read More »

A study of IDIBELL and IDIBGI evaluates the efficacy of an anti-tumour drug against obesity

The drug inhibits the S6K1 protein, which is essential for the development of new fat cells, responsible for the disproportionate growth of fat deposits in obese people.

A study of IDIBELL and IDIBGI evaluates the efficacy of an anti-tumour drug against obesity Read More »

A generic antiviral could improve the life expectancy of patients with a rare disease without a cure

IDIBELL and Hospital de Bellvitge are studying the efficacy of Efavirenz, an antiretroviral against HIV, for the treatment of Niemann Pick type C in a clinical trial.

A generic antiviral could improve the life expectancy of patients with a rare disease without a cure Read More »

Scroll to Top